Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Huntington's disease (HD) is characterized by basal ganglia circuitry dysfunction.
• Reduced striatal phosphodiesterase 10 (PDE10) levels are observed in HD patients and models.
• Impaired cyclic nucleotide signaling is a hallmark of HD.

Purpose of the Study:

• To investigate the therapeutic potential of PDE10 inhibition in HD models.
• To elucidate the mechanisms underlying PDE10's role in basal ganglia function in HD.

Main Methods:

• Utilized Huntington's disease mouse models with reduced PDE10 levels.
• Administered pharmacologic PDE10 inhibitors acutely and chronically.
• Performed phosphoproteomic profiling of the striatum.
• Assessed basal ganglia circuitry function, corticostriatal input, and indirect pathway activity.

Main Results:

• Acute PDE10 inhibition corrected basal ganglia circuitry deficits and restored corticostriatal input.
• Both cAMP and cGMP elevation were necessary for the therapeutic effect.
• Phosphoproteomic analysis identified neural substrates involved in the observed improvements.
• Early chronic PDE10 inhibition prevented neurophysiological deficits and reversed transcriptomic alterations.

Conclusions:

• Pharmacologic PDE10 inhibition is a promising therapeutic strategy for Huntington's disease.
• PDE10 inhibition normalizes cyclic nucleotide signaling and restores basal ganglia function.
• Early intervention with PDE10 inhibitors may offer disease-modifying benefits in HD.